Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

704 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The regulatory T cell-selective interleukin-2 receptor agonist rezpegaldesleukin in the treatment of inflammatory skin diseases: two randomized, double-blind, placebo-controlled phase 1b trials.
Silverberg JI, Rosmarin D, Chovatiya R, Bieber T, Schleicher S, Beck L, Gooderham M, Chaudhry S, Fanton C, Yu D, Levy J, Liu Y, Miyazaki T, Tagliaferri M, Schmitz C, Nirula A, Kotzin B, Zalevsky J. Silverberg JI, et al. Nat Commun. 2024 Oct 25;15(1):9230. doi: 10.1038/s41467-024-53384-1. Nat Commun. 2024. PMID: 39455575 Free PMC article. Clinical Trial.
Efficacy, Safety, and Long-Term Disease Control of Ruxolitinib Cream Among Adolescents with Atopic Dermatitis: Pooled Results from Two Randomized Phase 3 Studies.
Eichenfield LF, Simpson EL, Papp K, Szepietowski JC, Blauvelt A, Kircik L, Silverberg JI, Siegfried EC, Kuligowski ME, Venturanza ME, Kallender H, Ren H, Paller AS. Eichenfield LF, et al. Among authors: silverberg ji. Am J Clin Dermatol. 2024 Jul;25(4):669-683. doi: 10.1007/s40257-024-00855-2. Epub 2024 May 2. Am J Clin Dermatol. 2024. PMID: 38698175 Free PMC article. Clinical Trial.
Lebrikizumab Provides Rapid Clinical Responses Across All Eczema Area and Severity Index Body Regions and Clinical Signs in Adolescents and Adults with Moderate-to-Severe Atopic Dermatitis.
Simpson EL, de Bruin-Weller M, Hong HC, Staumont-Sallé D, Blauvelt A, Eyerich K, Gooderham M, Shahriari M, Mallbris L, Atwater AR, Rueda MJ, Ding Y, Liu Z, Agell H, Silverberg JI. Simpson EL, et al. Among authors: silverberg ji. Dermatol Ther (Heidelb). 2024 May;14(5):1145-1160. doi: 10.1007/s13555-024-01158-4. Epub 2024 May 3. Dermatol Ther (Heidelb). 2024. PMID: 38700646 Free PMC article.
Nemolizumab with concomitant topical therapy in adolescents and adults with moderate-to-severe atopic dermatitis (ARCADIA 1 and ARCADIA 2): results from two replicate, double-blind, randomised controlled phase 3 trials.
Silverberg JI, Wollenberg A, Reich A, Thaçi D, Legat FJ, Papp KA, Stein Gold L, Bouaziz JD, Pink AE, Carrascosa JM, Rewerska B, Szepietowski JC, Krasowska D, Havlíčková B, Kalowska M, Magnolo N, Pauser S, Nami N, Sauder MB, Jain V, Padlewska K, Cheong SY, Fleuranceau Morel P, Ulianov L, Piketty C; ARCADIA 1 and ARCADIA 2 Study Investigators. Silverberg JI, et al. Lancet. 2024 Aug 3;404(10451):445-460. doi: 10.1016/S0140-6736(24)01203-0. Epub 2024 Jul 24. Lancet. 2024. PMID: 39067461 Clinical Trial.
More Time Spent with Clear Skin and No Itch with Upadacitinib versus Dupilumab for Atopic Dermatitis.
Blauvelt A, Eyerich K, Irvine AD, de Bruin-Weller M, Kwatra SG, Gooderham M, Kim B, Calimlim BM, Lee WJ, Raymundo EM, Liu Y, Ofori S, Platt AM, Silverberg JI. Blauvelt A, et al. Among authors: silverberg ji. Dermatol Ther (Heidelb). 2024 Sep;14(9):2621-2630. doi: 10.1007/s13555-024-01242-9. Epub 2024 Aug 7. Dermatol Ther (Heidelb). 2024. PMID: 39110139 Free PMC article.
A Scalable Approach to Assess the Safety of Recently Marketed Systemic Treatments for Atopic Dermatitis in Clinical Practice: First Analysis Cycle of a Sequential Monitoring System.
Schneeweiss MC, Glynn RJ, Wyss R, Anand P, Jin Y, Landon J, Mostaghimi A, Merola JF, Silverberg JI, Rosmarin DM, Sidbury R, Schneeweiss S. Schneeweiss MC, et al. Among authors: silverberg ji. J Invest Dermatol. 2024 Oct 1:S0022-202X(24)02169-9. doi: 10.1016/j.jid.2024.08.034. Online ahead of print. J Invest Dermatol. 2024. PMID: 39362623
Dupilumab treatment improves signs, symptoms, quality of life, and work productivity in patients with atopic hand and foot dermatitis: Results from a phase 3, randomized, double-blind, placebo-controlled trial.
Simpson EL, Silverberg JI, Worm M, Honari G, Masuda K, Syguła E, Schuttelaar MLA, Mortensen E, Laws E, Akinlade B, Patel N, Maloney J, Paleczny H, Delevry D, Xiao J, Dubost-Brama A, Bansal A. Simpson EL, et al. Among authors: silverberg ji. J Am Acad Dermatol. 2024 Jun;90(6):1190-1199. doi: 10.1016/j.jaad.2023.12.066. Epub 2024 Feb 1. J Am Acad Dermatol. 2024. PMID: 38296199 Free article. Clinical Trial.
Efficacy and safety of crisaborole ointment, 2%, in participants aged ≥45 years with stasis dermatitis: Results from a fully decentralized, randomized, proof-of-concept phase 2a study.
Silverberg JI, Kirsner RS, Margolis DJ, Tharp M, Myers DE, Annis K, Graham D, Zang C, Vlahos BL, Sanders P. Silverberg JI, et al. J Am Acad Dermatol. 2024 May;90(5):945-952. doi: 10.1016/j.jaad.2023.12.048. Epub 2024 Feb 8. J Am Acad Dermatol. 2024. PMID: 38340127 Free article. Clinical Trial.
704 results